Prox Biosciences develops cis-targeting biologics that enhance immune response through advanced antibody engineering and computational methods. The company aims to provide effective and safe treatments for patients with fatal and debilitating diseases by precisely controlling biological pleiotropism.
Funding
Funding not disclosed
Founders
Product
Problem
Many immunotherapies lack precise control over their biological effects, leading to off-target effects and limited efficacy in treating complex diseases. Existing approaches often struggle to achieve optimal dosing, safety, and efficacy due to the pleiotropic nature of biological systems.
Solution
Prox Biosciences engineers cis-targeting biologics designed to enhance immune responses with greater precision and control. By leveraging advanced antibody engineering and computational methods, the company aims to rewire immunity and precisely control biological pleiotropism. This approach seeks to deliver treatments with improved dosing, safety, and efficacy for patients facing fatal and debilitating diseases. The cis-targeting mechanism focuses the therapeutic effect on specific cells or tissues, minimizing systemic exposure and potential side effects.
Target Audience
The primary target audience includes patients with fatal and debilitating diseases who may benefit from more effective and safer immunotherapies, as well as researchers and clinicians in the fields of immunology and oncology.
Features
- Cis-targeting biologics for precise immune modulation
- Advanced antibody engineering to optimize target specificity and affinity
- Computational methods for rational design and prediction of biological effects